US2019135827A1PendingUtilityA1

Substituted Tricyclics and Method of Use

57
Assignee: ABBVIE SARLPriority: Jul 16, 2015Filed: Jan 8, 2019Published: May 9, 2019
Est. expiryJul 16, 2035(~9 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 11/00A61K 31/433A61K 45/06C07D 405/12C07D 317/70C07D 519/00A61K 31/357A61K 31/397A61K 31/4709A61K 31/443A61K 31/501A61K 31/4439A61K 31/5377C07D 493/04C07D 407/12A61K 31/4545A61K 31/497A61K 31/4436A61K 31/36A61K 31/4433A61K 31/453A61K 31/426A61K 31/4184A61K 31/404
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides for compounds of formula (I) wherein X, Y, and R 1 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by CFTR, including cystic fibrosis, Sjögren's syndrome, pancreatic insufficiency, chronic obstructive lung disease, and chronic obstructive airway disease. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A compound having the formulae: 
       
         
           
           
               
               
           
         
       
       wherein one or more hydrogen atoms are replaced by deuterium;
 or a pharmaceutically acceptable salt thereof.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.